Benzinga

Benzinga

Benzinga

lundi, août 31

Quest Diagnostics Inc

DGXNYSE
Trade with Public
Trade with Public
$242.76
-1.85-0.76%
À la clôture: Aug 27, 5:00 PM EST
$242.77
-1.84-0.75%
Pré-ouverture: 8:56 AM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatDividendesComparerOptionsRapport sur les stocks

Quest Diagnostics Financials

Quest Diagnostics (DGX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning

Quest Diagnostics (NYSE: DGX) stock jumps after Q2 earnings beat estimates and full-year 2026 guidance gets a boost.
Vandana Singh

Earnings Scheduled For July 23, 2026

Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is expected to report
Benzinga Insights

PRO
Quest Diagnostics Raises FY2026 Adj EPS Guidance from $10.63-$10.83 to $11.05-$11.25 vs $10.76 Est; Raises FY2026 Sales Guidance from $11.780B-$11.900B to $11.950B-$12.050B vs $11.851B Est

Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $10.63-$10.83 to $11.05-$11.25 vs $10.76 analyst estimate. Raises FY2026 sales outlook from $11.780 billion-$11.900 billion to $11.950 billion-$12.050
Benzinga Newsdesk

PRO
Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 Est

Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 analyst estimate..
Benzinga Newsdesk

PRO
Quest Diagnostics Q2 Adj. EPS $3.12 Beats $2.83 Estimate, Sales $3.043B Beat $2.973B Estimate

Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $3.12 per share which beat the analyst consensus estimate of $2.83 by 10.25 percent. This is a 19.08 percent increase over earnings of $2.62 per share from the
Benzinga Newsdesk

These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings

Quest Diagnostics (DGX) reported strong Q1 earnings, beating expectations and raising guidance. Analysts maintain positive outlook on stock.
Avi Kapoor

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved